Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Novavax inks $1.6B Warp Speed deal to fund COVID vaccine's phase 3 testing, manufacturing
Regeneron bags $450M deal with U.S. government for coronavirus antibody cocktail supply
Fauci says U.S. 'still knee-deep in the first wave' of COVID-19 as daily cases top 50K
Moderna delay a snapshot of 'squabbles' with U.S. scientists over COVID-19 vaccine trials: Reuters
Mayo Clinic CEO blasts 'just-in-time' ordering as pandemic changes supply chain
EU in 'constructive' talks with Gilead to nab remdesivir amid U.S. supply grab: report
GlaxoSmithKline pens COVID-19 vaccine pact with Medicago
Healthcare roundup: Alabama hospital suspends some surgeries as cases spike
Biopharma roundup: J&J updates Catalent pact for Italian shot finishing; LabCorp launches at-home test collection service
Verma: COVID-19 proving the need for greater interoperability
CMS proposes Medicare payment updates to increase use of home dialysis
Pharma's pandemic response could help attract tech talent, Novartis digital chief says

Featured Story

Novavax inks $1.6B Warp Speed deal to fund COVID vaccine's phase 3 testing, manufacturing

By Eric Sagonowsky

Novavax and its COVID-19 shot are racing against well-funded global pharmaceutical players, but a new deal with the U.S. government will push the biotech's fundraising haul past $2 billion. Under the deal, the biotech will start producing 100 million doses of its later this year.

Regeneron bags $450M deal with U.S. government for coronavirus antibody cocktail supply

By Kyle Blankenship

Among the drugmakers seeking an answer for COVID-19, Regeneron once showed promise in its quest to repurpose an older therapy as a treatment and develop a novel antibody cocktail. Now, thanks to disappointing data, that first path appears blocked—but Regeneron will sport a major U.S. investment for its antibody hopeful.

Fauci says U.S. 'still knee-deep in the first wave' of COVID-19 as daily cases top 50K

By Robert King

Infectious disease expert Anthony Fauci cautioned the U.S. is not seeing the start of a second wave of novel coronavirus because the first wave has still not ended.

Moderna delay a snapshot of 'squabbles' with U.S. scientists over COVID-19 vaccine trials: Reuters

By Amirah Al Idrus

Late last week, Stat reported that Moderna would delay the phase 3 study of its COVID-19 vaccine, thanks to changes to the trial’s protocols. Such changes are not uncommon, highlighting just how closely watched anti-COVID-19 efforts are, but the delay is part of a trend of tensions in the biotech’s relationship with the U.S. government.

Mayo Clinic CEO blasts 'just-in-time' ordering as pandemic changes supply chain

By Robert King

The head of Mayo Clinic said the COVID-19 pandemic will change how the system approaches supply chain management.

EU in 'constructive' talks with Gilead to nab remdesivir amid U.S. supply grab: report

By Angus Liu

After the Trump administration locked up almost all doses of Gilead Sciences’ COVID-19 treatment remdesivir for the next few months, Europe decided it needs to look out for itself, too. The EU health commissioner reportedly spoke with Gilead execs Monday to iron out a supply deal.

GlaxoSmithKline pens COVID-19 vaccine pact with Medicago

By Ben Adams

Hoping to broaden shots on target, GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Healthcare roundup: Alabama hospital suspends some surgeries as cases spike

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: J&J updates Catalent pact for Italian shot finishing; LabCorp launches at-home test collection service

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

Johnson & Johnson updated its pact with Catalent to secure shot finishing at the CDMO's Italian site. CureVac nabbed $85 million from the EU to scale its mRNA vaccine production. LabCorp launched a new COVID-19 test collection service, and President Donald Trump is touting hydroxychloroquine—again.

Verma: COVID-19 proving the need for greater interoperability

By Paige Minemyer

Centers for Medicare & Medicaid Services Administrator Seema Verma said the COVID-19 pandemic has “exposed a lot of inefficiencies” in the healthcare system—with one of the largest being data sharing and access.

CMS proposes Medicare payment updates to increase use of home dialysis

By Paige Minemyer

The Trump administration has proposed an enhanced Medicare add-on payment to encourage greater use of home dialysis for beneficiaries with end-stage renal disease.

Pharma's pandemic response could help attract tech talent, Novartis digital chief says

By Beth Snyder Bulik

The COVID-19 pandemic changed consumer perceptions of the pharma industry, but it changed some professionals' minds, too. Almost three-fourths (73% ) of tech professionals say their opinion of the industry has improved during the pandemic, thanks to its response in the search for treatments and vaccines, according to a new Novartis study.

COVID-19 Tracker

Featured Story

Novavax inks $1.6B Warp Speed deal to fund COVID vaccine's phase 3 testing, manufacturing

Top Stories

Regeneron bags $450M deal with U.S. government for coronavirus antibody cocktail supply

Fauci says U.S. 'still knee-deep in the first wave' of COVID-19 as daily cases top 50K

Moderna delay a snapshot of 'squabbles' with U.S. scientists over COVID-19 vaccine trials: Reuters

Mayo Clinic CEO blasts 'just-in-time' ordering as pandemic changes supply chain

EU in 'constructive' talks with Gilead to nab remdesivir amid U.S. supply grab: report

GlaxoSmithKline pens COVID-19 vaccine pact with Medicago

Healthcare roundup: Alabama hospital suspends some surgeries as cases spike

Biopharma roundup: J&J updates Catalent pact for Italian shot finishing; LabCorp launches at-home test collection service

Verma: COVID-19 proving the need for greater interoperability

CMS proposes Medicare payment updates to increase use of home dialysis

Pharma's pandemic response could help attract tech talent, Novartis digital chief says